D-A Ertl, G Mantovani, G P de Nanclares, F M Elli, A Pereda, A Pagnano, A Sanchis, A M Cueto-Gonzalez, S Berrade, M C León, A Rothenbuhler, C Audrain, J Berkenou, N Knight, K Dolman, A Gleiss, J Argente, A Linglart
INTRODUCTION: Severe short stature is a feature of acrodysostosis, but data on growth are sparse. Treatment with recombinant human growth hormone (rhGH) is used in some centers to increase final height, but no studies have been published so far. Our objective was to conduct a multicenter, retrospective, cohort study to investigate growth in individuals with both types of acrodysostosis, treated with rhGH or not; we used the new nomenclature to describe acrodysostosis, as this disease belongs to the large group of inactivating PTH/PTHrP signaling disorders (iPPSD); acrodysostosis refers to iPPSD4 (acrodysostosis type 1 due to PRKAR1A mutations) and iPPSD5 (acrodysostosis type 2, due to PDE4D mutations)...
February 7, 2023: Journal of Endocrinological Investigation